NCT00792467View on ClinicalTrials.gov

Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

September 30, 2010

Conditions
Hodgkin's Lymphoma
Interventions
DRUG

ITF2357

ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.

Trial Locations (1)

20133

Istituto Nazionale per la Cura e lo Studio dei Tumori, Milan

Sponsors

Lead Sponsor

Italfarmaco
All Listed Sponsors
lead

Italfarmaco

INDUSTRY